Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.54 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TK1 | P04183 | 1/20 | 0.50 |
| ▸ | DTYMK | P23919 | 2/20 | 0.49 |
| ▸ | TK2 | O00142 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxribtimine SCHEMBL6518312 | 1.00 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| Doxribtimine SCHEMBL29124320 | 0.96 | P2RY2 (0.60) | LMNATHRBMTORMDM2NCOA1 | |
| Doxribtimine SCHEMBL3951759 | 0.92 | TK1 (0.56) | LMNASMN1; SMN2TK1TK2 | |
| Cytidine SCHEMBL4468985 | 0.90 | LMNA (0.65) | LMNATHRBMTORMDM2NCOA1 | |
| Adenosine SCHEMBL23835231 | 0.89 | DTYMK (0.66) | SMN1; SMN2DTYMK | |
| Cytidine SCHEMBL574775 | 0.88 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| Guanosine SCHEMBL10528215 | 0.87 | F2 (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| Cytidine SCHEMBL574822 | 0.87 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| Doxecitine SCHEMBL9803658 | 0.87 | LMNA (0.50) | LMNASMN1; SMN2TK1TK2 | |
| Doxribtimine SCHEMBL325199 | 0.87 | TK1 (0.62) | LMNASMN1; SMN2TK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190003966-A1 | Ultraviolet and High-Performance Liquid Chromatography Methods for the Evaluation of Sunscreen Efficacy | SENA RESEARCH, INCORPORATED (US) | 2019-01-03 | — | — | US | claimed |
| US-20130183765-A1 | Ultraviolet and High-Performance Liquid Chromatography Methods for the Evaluation of Sunscreen Efficacy | Sena Research Incorporated (US) | 2013-07-18 | — | — | US | claimed |
| WO-2012037158-A2 | ULTRAVIOLET AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHODS FOR THE EVALUATION OF SUNSCREEN EFFICACY | SENA RESEARCH, INCORPORATED (US) | 2012-03-22 | — | — | WO | claimed |
| WO-2009027507-A2 | APTAMERS WHICH BIND TO A TARGET MOLECULE INVOLVED IN HAEMOSTASIS | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT (DE) | 2009-03-05 | — | — | WO | claimed |
| CN-117016549-B | Application of nucleoside compound and composition thereof in promoting plant growth | 山东蓬勃生物科技有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117016549-A | Application of nucleoside compound and composition thereof in promoting plant growth | 山东蓬勃生物科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20190003966-A1 | Ultraviolet and High-Performance Liquid Chromatography Methods for the Evaluation of Sunscreen Efficacy | SENA RESEARCH, INCORPORATED (US) | 2019-01-03 | — | — | US | disclosed |
| US-10073033-B2 | Ultraviolet and high-performance liquid chromatography methods for the evaluation of sunscreen efficacy | SENA RESEARCH, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| US-20130183765-A1 | Ultraviolet and High-Performance Liquid Chromatography Methods for the Evaluation of Sunscreen Efficacy | Sena Research Incorporated (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2012037158-A2 | ULTRAVIOLET AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHODS FOR THE EVALUATION OF SUNSCREEN EFFICACY | SENA RESEARCH, INCORPORATED (US) | 2012-03-22 | — | — | WO | disclosed |
| US-7700761-B2 | 3-deoxypentopyranosyl nucleic acid, its production and its use | NANOGEN RECOGNOMICS GMBH (DE) | 2010-04-20 | — | — | US | disclosed |
| WO-2009027507-A2 | APTAMERS WHICH BIND TO A TARGET MOLECULE INVOLVED IN HAEMOSTASIS | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT (DE) | 2009-03-05 | — | — | WO | disclosed |
| US-20060217546-A1 | 3-Deoxypentopyranosyl nucleic acid, its production and its use | SANOFI (FR) | 2006-09-28 | — | — | US | disclosed |
| EP-1102782-A4 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | BIO RAD LABORATORIES (US) | 2002-01-30 | — | — | EP | disclosed |
| US-6310189-B1 | NUCLEOSIDE PHOSPHORAMIDITES OR NUCLEOSIDE H-PHOSPHONATES HAVING A PHOTOREMOVEABLE PROTECTING GROUP COVALENTLY ATTACHED TO A C-3' OR C5' OXYGEN ATOM; PHOTOLITHOGRAPHY; MINIATURIZATION; FINENESS | AFFYMETRIX, INC. | 2001-10-30 | — | — | US | disclosed |
| EP-1102782-A1 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | Bio-Rad Laboratories (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008041-A9 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | BIO RAD LABORATORIES (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2000008041-A1 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | BIO-RAD LABORATORIES (US) | 2000-02-17 | — | — | WO | disclosed |
| US-4788181-A | 5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1988-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217546-A1 | 3-Deoxypentopyranosyl nucleic acid, its production and its use | RNGTT, DTYMK, MTAP | LMNA 1658/4885THRB 4486/4885MTOR 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.